- Home
- / Inhibitor Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Inhibitor Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2024-10-29
Market Capitalization
$12.9 M
2024-10-29
CreditSafe Score
?
Score changed on Mar 16, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 817.3K | 1.5M | 2.3M | 4.4M | 2.9M | 1.9M | 1.5M | 873.7K | 320.5K | 651.8K | 2.0M |
| Operating expense total | 1.9M | 3.9M | 3.9M | 7.0M | 5.1M | 4.6M | 2.7M | 1.1M | 657.9K | 3.4M | |
| EBIT | (2.0M) | (3.9M) | (3.9M) | (7.0M) | (5.1M) | (4.6M) | (2.7M) | (1.1M) | (325.4K) | (657.9K) | (3.4M) |
| Interest income | 378.8K | ||||||||||
| Interest expense | 22.0K | 17.9K | 14.0K | 14.5K | 1.1K | (14.8K) | |||||
| Pre tax profit | 12.2M | (3.0M) | |||||||||
| Income tax expense | 55.1K | ||||||||||
| Net Income | (1.8M) | (4.0M) | (3.9M) | (7.0M) | (5.1M) | (4.6M) | (2.7M) | (1.1M) | (298.6K) | 12.1M | (3.0M) |
| EPS | 0.0 | 0.0 |